LLY
StockEli Lilly and Co
- HQ
- US
- Sector
- Pharmaceuticals
- Issued
- 1985-01-13
- Shares out.
- 942M
Performance
2 h agoKey statistics
2 h ago- Market cap
- $1.02T
- Enterprise value
- $1.05T
- P/E (TTM)
- 40.16
- Forward P/E
- 27.51
- P/E (annual)
- 49.19
- PEG
- 1.37
- P/B
- 38.29
- P/S (TTM)
- 14.05
- P/S (annual)
- 15.58
- EV / EBITDA
- 31.38×
- EV / Revenue
- 14.58×
- EPS (TTM)
- $28.15
- EPS (annual)
- $22.95
- Basic EPS (TTM)
- $28.15
- Book value / share
- $28.09
- Gross margin
- 82.83%
- Operating margin
- 43.63%
- Net margin
- 34.99%
- Return on equity (ROE)
- 101.31%
- Return on assets (ROA)
- 22.73%
- Return on investment (ROI)
- 37.71%
- EBITDA / share
- $37.37
- Revenue / share (TTM)
- $80.64
- Revenue growth (TTM YoY)
- +47.44%
- Revenue growth (Q YoY)
- +55.55%
- EPS growth (TTM YoY)
- +128.83%
- Dividend yield (indicated)
- 0.64%
- Dividend yield (TTM)
- 0.55%
- Dividend / share (TTM)
- $5.91
- Payout ratio
- 22.10%
- Current ratio
- 1.58
- Quick ratio
- 0.78
- Debt / equity
- 1.60
- LT debt / equity
- 1.54
- Beta
- 0.52
- Volatility (3M)
- 37.57%
Analyst ratings
2 h agoEarnings
2 h agoRelated news
2 h ago- Yahoo·7 d agocompanyLimmaTech Biologics to be Acquired by Lilly for Next-generation Vaccines Against Common Bacterial Infections
SCHLIEREN (ZURICH), Switzerland, May 26, 2026--LimmaTech Biologics AG, a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly.
- Yahoo·7 d agocompanyVaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases
Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly.
- Yahoo·7 d agocompanyCurevo to be Acquired by Lilly to Advance Next-Generation Shingles Prevention
Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved productsSEATTLE, May 26, 2026 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive agreement to be acquired by Lilly. Curevo’s lead product candidate is amezosvatein, an a
- Yahoo·7 d agocompanyLilly announces three acquisitions to build infectious disease portfolio
Eli Lilly and Company (NYSE: LLY) today announced agreements to acquire three companies, Curevo Inc. (Curevo), LimmaTech Biologics AG (LimmaTech Biologics), and Vaccine Company, Inc. (Vaccine Company), that expand its research and development efforts into infectious disease. The transactions advance Lilly's strategy of investing in differentiated technology platforms to address significant health problems.
- Yahoo·7 d agocompanyWall Street Set for Gains as Iran Peace Hopes Hold: Markets Wrap
(Bloomberg) -- US equity futures gained and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on Uranium
- CNBC·7 d agocompanyCramer’s Mad Dash: Eli Lilly
CNBC’s Jim Cramer delivers his daily Mad Dash.
- Yahoo·7 d agocompanyPrediction: These 2 Obesity Drug Stocks Could Double in 2026
These players are seeing exciting results in clinical trials.
- SeekingAlpha·7 d agocompanyLeqembi Isn't Enough To Save Biogen Momentum (Rating Downgrade)
